#USA #St. Paul #Zepto Life Technology #FungiFlex® #Pneumocystis jirovecii

Zepto Life Technology Expands FungiFlex® Testing Options

In a significant advancement for the field of molecular diagnostics, Zepto Life Technology has unveiled its latest offerings in the FungiFlex® product line. Two new liquid biopsy assays have been introduced: the FungiFlex® Pneumocystis jirovecii and the FungiFlex® Mold Plus Panel. These additions aim to improve the detection of fungal pathogens, particularly in patients with weakened immune systems.

The Need for Advanced Testing

Patients most vulnerable to infections caused by Pneumocystis jirovecii (PCP) and invasive molds often include transplant recipients, individuals undergoing treatment for hematologic malignancies, and those with other conditions that compromise their immune defenses. The urgency for precise and prompt diagnostic tools in these high-risk populations has led to a demand from clinicians for enhanced testing options.

Before the introduction of FungiFlex®, the available testing methods did not comprehensively address the clinical needs for simultaneous evaluation of different fungal pathogens. Recognizing this gap, Zepto Life Technology has responded with two exciting new testing solutions that cater directly to the requests of healthcare professionals.

FungiFlex® Pneumocystis jirovecii: Targeted Testing

The FungiFlex® Pneumocystis jirovecii assay is designed to provide targeted detection of P. jirovecii using plasma cell-free DNA (cfDNA) technology. This approach allows clinicians to obtain vital diagnostic information with minimal invasiveness, facilitating timely clinical decisions.

FungiFlex® Mold Plus Panel: Combining Tests

The FungiFlex® Mold Plus Panel brings a unique solution by combining the detection of various invasive mold pathogens along with P. jirovecii into a single test. This integrated approach streamlines the diagnostic process for clinicians, who can now evaluate multiple fungal infections simultaneously instead of performing separate tests.

Meeting Clinical Demands

According to Hannah Zhang, CEO of Zepto Life Technology, the integration of P. jirovecii into the FungiFlex® testing menu was a direct response to consistent feedback from clinicians. “Our customers' requests have been the most rewarding part of launching FungiFlex®. This expansion reflects real-world practices in how fungal infections are diagnosed today,” she explained.

Summary of FungiFlex® Test Options

The FungiFlex® test menu, now more diverse than ever, includes:
1. FungiFlex® Mold Panel - This panel detects 14 different species of invasive mold pathogens, including common culprits such as Aspergillus and Fusarium.
2. FungiFlex® Pneumocystis jirovecii - A targeted assay for the detection of P. jirovecii.
3. FungiFlex® Mold Plus Panel - A combined panel that identifies both invasive mold pathogens and P. jirovecii from a single plasma sample.

Testing is conducted at Zepto Life Technology's CLIA-certified reference laboratory, with results typically reported within 24 hours of sample receipt. This quick turnaround is crucial for effective patient management in critical care situations.

Looking Ahead

The recent additions to the FungiFlex® testing lineup signal Zepto Life Technology's commitment to evolving its offerings in line with clinical needs. The company has plans to continue enhancing its suite of tests, adding more targeted plasma cfDNA assays to address other significant gaps in fungal diagnostics.

As healthcare continues to embrace the potential of molecular diagnostics, innovations like the FungiFlex® menu play a critical role in improving patient outcomes. With these new testing options, clinicians are better equipped to manage infections in high-risk patients, ultimately leading to improved survival rates and enhanced quality of care.

For more details on Zepto Life Technology and its products, please visit www.zeptolife.com.